A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
Status:
Completed
Trial end date:
2018-09-20
Target enrollment:
Participant gender:
Summary
The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may
safely be used for the elderly patients with renal dysfunction. Grazoprevir and elbasvir are
metabolized in the liver and do not require dose-adjustment for patients with renal
dysfunction. However, no data related to efficacy and safety of the grazoprevir plus elbasvir
treatment for Japanese elderly patients with renal dysfunction (eGFR<60 mL/min/1.73m2) have
been reported. Therefore, physicians are at a loss whether or not to treat the patients with
renal dysfunction due to no evidence.
The aim of this study is to investigate the improvement of serum endostatin level of Japanese
patients with CKD stage 3 after grazoprevir (NS3/4A protease inhibitor) plus elbasvir (NS5A
replication complex inhibitor) treatment by a prospective, multicenter cohort study.